Akriveia Therapeutics Raises $7.5M

Thousand Oaks-based Akriveia Therapeutics, a biotechnology startup focused on immuno-oncology, announced this morning that it has raised $7.5M in a Series A investment. The investment came from F-Prime Capital Partners. Akriveia Therapeutics said it is developing immunotherapeutic products that are specifically activated in the microenvironment of the tumor. As part of the funding, F-Prime's Thomas Beck and Ben Auspitz have joined the company's board. Akriveia is led by Simon Tomlinson. The company said its technology is based on research from the labs of Professor John Williams at City of Hope and Professor Ulrich Rodeck at Thomas Jefferson University. More information »